



# EVÖQ nano

**Engineering novel nanoparticles for the life science, materials science, and textile science industries.**

EVÖQ Nano is a nanoscience company that has developed a multi-patented, high-volume laser nanofabrication process that creates uniform, stable, sub-10 nm nanoparticles with distinct surface chemistry suitable for a wide range of applications.

This proprietary process uses only lasers, liquid, and natural absorptive materials. The simplicity and purity of this method enables the creation of novel nanoparticles without toxic byproducts or waste streams.

---

## Key Benefits of EVÖQ Nano's Discrete Nanoparticles

- **Uniform Sub-10 nm:** Enables effective cell interaction and offers a high surface-area-to-volume ratio with repeatable results.
- **Non-Ionic:** Efficacy without the risks and limitations linked to ion emission.
- **Non-Oxidative:** Mitigates need for added stabilizers and surface coatings.
- **Non-Toxic/Environmentally Friendly:** No toxic byproducts created in the manufacturing process.

## EVÖQ Nano Is Currently Focused on Developing Nanoparticles for 3 Core Industries

**EVÖQ Bio** has pioneered a nanomedicine platform with demonstrated antimicrobial efficacy against the world's worst superbugs. In partnership with the Cystic Fibrosis Foundation, the company has developed a lead therapeutic and had its Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) in March 2024 and is confidently advancing toward Phase I clinical trials.

**EVÖQ MedTech** offers a breakthrough nanotechnology platform that integrates antimicrobial capabilities into medical devices to defend against a broad spectrum of contaminants like bacteria and fungi. The company has partnered with seven of the top catheter manufacturers with the aim of curbing healthcare-associated infections (HAIs).

**FUZE Technologies** is an antimicrobial solutions company serving the textile, hospitality, fitness, and workspace industries. Its EPA-approved antimicrobial technology is free of chemicals, toxicity, and environmental waste. The company has secured contracts with some of the world's most notable brands, including Nike, Adidas, the New England Patriots, Marriott, and Hilton.



## The Niedermeyer Discovery

A lifelong scientist with a background in applied physics, EVÖQ Nano Co-Founder and Chief Technology Officer William Niedermeyer values focused research. He has led several research and development programs within instrumental ion physics in the private and corporate sectors, applying his physics background in several groundbreaking technologies. When the events of 9/11 suspended his doctoral studies in high-energy physics at the University of Utah, Niedermeyer pivoted to the burgeoning nanotechnology field, intrigued by its potential applications in medicine, renewable energy, and microelectronics.

With proceeds from his first company, in 2001 Niedermeyer started a small laboratory to investigate nanoparticles and their properties. Early efforts were frustrated, however, by recurring problems with nanoparticle impurity, uneven size distribution, agglomeration into large clumps, low energy emission, and colloidal instability. Plus, purchasing diverse nanoparticles in bulk to conduct research was incredibly expensive.

Motivated to remedy these limitations, Niedermeyer engineered his own nanofabrication process using modified laser equipment and parts from the previous Star Wars program at Lawrence Livermore National Laboratory. To his amazement, this invention produced nanoparticles unlike any he had studied. They were uniformly sized, surfactant-free, with consistent spherical morphology, and no ion emissions under standard and stressed conditions – properties that represented a significant advancement in nanoscience with the potential to enable new applications.

In 2011, Niedermeyer and his team patented the unique laser-based nanofabrication process and the resulting “Niedermeyer Particle.” Starting with 3 initial patents, the company has grown its intellectual portfolio to include 39 issued and 39 pending patents as of 2023.

## Leadership

Shaun Rothwell, Chairman & CEO

Jeff Bennion, Chief Financial Officer

David Nilson, Chief Development Officer

William Niedermeyer, Founder and Chief Technology Officer

Steve Savage, President of FUZE Technologies

Andrew Peterson, Chief Technical Officer

Charles Wright, President of MedTech & Bio

Nate Kerr, Vice President of Medical Operations

## Investors, Partners, and Affiliations

EVÖQ Nano is backed by \$20 million in seed funding. The company has R&D partnerships with the University of Utah Nanofab & Health Core Sciences, National Science Foundation Materials Research Science and Engineering Center, Cystic Fibrosis Foundation, Charles River Laboratories, Lovelace Biomedical, Seattle Children’s Research Institute, Accugen Laboratories, Stillmeadow Inc, Healthcare Innovation & Technology Lab, Galbraith Laboratories, Nelson Laboratories, Emery Laboratories, University of Washington, Arizona State University - EELS, and Utah State University.

## Headquarters

1895 W 2100 S  
Salt Lake City, UT 84119

**To learn more, visit [evoqnano.com](http://evoqnano.com)**

## Media Contact

Capwell Communications  
[media@capwellcomm.com](mailto:media@capwellcomm.com)